Funding & Disinvestments

The pharmaceutical company submitted bids across several critical childhood immunisation categories, including the Pneumococcal Conjugate Vaccine (PCV10), Rotavirus vaccine, and paediatric Hepatitis B vaccine.

The collaboration focuses on multiple research programmes designed to develop and commercialise site-specific recombinases for diseases characterised by severe unmet medical needs.

Governments and private institutions across the GCC are investing unprecedented sums into healthcare infrastructure, recruiting top talent, and acquiring cutting-edge technology.

Spread across approximately 20,000 square metres, the plant is equipped with automated production lines and advanced quality control laboratories built to international pharmaceutical standards.

The three-day international exhibition, taking place from April 22 to 24 at the Sarit Expo Centre, has attracted participants from across Africa and beyond, reflecting growing regional demand for advanced healthcare solutions.

The updated platform now connects customers with companies such as Twin Health, Curai Health, Wheel, Berry Street, and Aaptiv.

The two companies began collaborating in 2024 through an option and license agreement valued at up to USD 465 million, which granted Gilead access to Tubulis’ proprietary ADC platforms.

The agreement includes a USD135 million upfront payment to Sino Biopharmaceutical for worldwide rights, with up to USD1.39 billion in potential milestone payments based on development, regulatory approvals, and sales.

ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.